🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re proud of our cutting-edge manufacturing facilities, including our newest facility in California, designed to accelerate the commercialization of innovative therapies. Read more: bit.ly/4iJgYzl

As the year comes to a close, we are reflecting on both our accomplishments, and the opportunities ahead of us in 2025! Thank you to our talented team and dedicated partners for your continued commitment and support. Here’s to a great year ahead!

Our team is looking forward to attending the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco. It’s always a pleasure connecting with our peers and industry leaders from around the globe.

#BreakingNews: Today, we announced new data highlighting BOT/BAL across multiple lines of treatment in #ColorectalCancer. Find the details of our five #ASCOGI presentations here: bit.ly/3WoDjsb #GI25

#BreakingNews: Today, we announced the publication of new data in the Journal of Clinical Oncology. Read more about the findings here: bit.ly/4h6tRCh #ImmunoOncology #Sarcomas

Our CMO Steven O'Day, MD sat down with STAT to make the case for redefining how we measure success in #cancer treatment. bit.ly/41dm3Jz

Our CEO, Dr. Garo Armen, was honored to speak at the Second Annual Oncothon this past weekend, where he shared insights and a call to action for advancing innovation in pediatric cancer care. Hear more from OncoDaily: oncodaily.com/opinion/garo-a… #OncoThon2025

Join us today at #AACRIO25. We’re presenting new translational data from the ongoing Ph2 study in refractory #GastricCancer, evaluating BOT/BAL in combination with chemotherapy & MiNK Therapeutics allo-iNKTs (agenT-797). Learn more and view presentation details: bit.ly/4bcfqun

Yesterday at #AACRIO25, we presented new translational insights demonstrating the strong immune activation driven by BOT/BAL in combination with chemotherapy and MiNK Therapeutics' allo-iNKTs in refractory #GastricCancer. Read more about the data: bit.ly/4bcfqun

Colorectal cancer is the 2nd leading cause of cancer-related deaths worldwide. As we recognize #ColorectalCancerAwarenessMonth, we reaffirm our commitment to raising awareness, advancing education, and driving innovation in treatment options for those impacted by this disease.

Tune in to "The Top Line" by FierceBiotech! Our Chief Medical Officer, Dr. Steven O'Day, shares his insights on the latest innovations and the future of immunotherapy in colorectal cancer care. Listen here: bit.ly/4bUx06e #Oncology #CancerResearch #ColorectalCancer

Stay tuned for #AACR25, where Anthony El-Khoueiry will present data from our Phase 1 trial evaluating botensilimab/balstilimab in treatment-refractory hepatocellular carcinoma (HCC). Learn more: bit.ly/4ceezcU. #Immunotherapy #CancerResearch #Oncology

Looking ahead to #AACR25: Dr. Myriam Chalabi will present the first results from the NEOASIS trial, evaluating neoadjuvant botensilimab/balstilimab in MSI-H and MSS solid tumors. Learn more about the presentation: bit.ly/4ceezcU. #Immunotherapy #Oncology

Today at #AACR25, Dr. Myriam Chalabi presented the first results from the NEOASIS study, evaluating neoadjuvant botensilimab/balstilimab in early-stage MSS and MSI-H cancers, including colorectal and breast cancers. Learn more: bit.ly/3GGTiwM. #Oncology #ClinicalTrial

As Dr. Goldberg eloquently states, the time is now to evolve how we develop and assess innovative treatments. At Agenus, our mission is rooted in bringing potential life-changing therapies—like BOT/BAL—to patients who have long been underserved. #ColorectalCancer #Immunotherapy

At #AACR25 Dr. Chalabi participated in the session “Neoadjuvant Treatment Across Tumor Types: One Size Does Not Fit All,” discussing the current landscape and promising role of IO—including BOT/BAL studies. Learn more & view her NEOASIS presentation: lnkd.in/eqzP6-JF.

Today we shared our Q1 2025 financial results and highlighted key updates from our immuno-oncology pipeline. We remain committed to advancing the next generation of immunotherapies for individuals living with cancer. Access the Q1 report: bit.ly/4me9ohS.

We are pleased to welcome Dr. Richard Goldberg to Agenus as Chief Development Officer. A pioneer in gastrointestinal oncology, Dr. Goldberg will guide the advancement of our immuno-oncology programs. Read the full announcement: bit.ly/43sMgVm.

Agenus will present new data from its expanded MSS metastatic colorectal cancer cohort at #ESMOGI25. Access full details: bit.ly/3GXun8q. #ColorectalCancer #Immunotherapy #Oncology #ClinicalTrials

At #ASCO25, we shared new data highlighting botensilimab’s immune activation in MSS #colorectalcancer—a common, treatment-resistant form of the disease. These findings offer new insight into how these patients may respond at the immune level. Learn more: bit.ly/43QPLFf